TP53 and cancer: In breast carcinoma, TW activates Akt signaling to promote maintenance of cancer stem cell phenotypes [25], metabolic reprogramming via coordinated activation of Akt signaling and repression of p53 and invasion [26] and drug resistance by upregulation of Akt2 [27].